{"id":48357,"date":"2022-09-14T13:02:00","date_gmt":"2022-09-14T11:02:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/"},"modified":"2022-09-14T13:02:00","modified_gmt":"2022-09-14T11:02:00","slug":"onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/","title":{"rendered":"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022"},"content":{"rendered":"
\n

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc.<\/a> today announced a presentation of data from its ongoing Phase 2 study of pegsitacianine at the World Molecular Imaging Congress (WMIC), occurring September 27 \u2013 October 1, 2022. The presentation will be given during the Cancer: Innovations in Molecular Imaging session.\n<\/p>\n

<\/a><\/p>\n

\nDetails of the oral presentation are as follows:\n<\/p>\n\n\n\n\n
\n

\nPresentation Title\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nDetection of Residual Peritoneal Metastases following Cytoreductive Surgery, Using the pH-sensitive Micellar Imaging Agent Pegsitacianine: An Interim Review of an Ongoing Phase 2 Study<\/a>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPresenter\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nPatrick Wagner, MD, Department of Surgical Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate\/Time:\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nThursday, September 29, 3:12 – 3:22 PM EST\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout OncoNano Medicine<\/b>\n<\/p>\n

\nOncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image guided surgery and a platform of immune-oncology therapeutics that activate and guide the body\u2019s immune system to target cancer.\n<\/p>\n

\nOncoNano\u2019s lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ON-BOARD platform, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNano\u2019s second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at www.OncoNano.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMacDougall Advisors
\n
Lauren Arnold
\n
larnold@macdougall.bio<\/a>
(617) 694-5387\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced a presentation of data from its ongoing Phase 2 study of pegsitacianine at the World Molecular Imaging Congress (WMIC), occurring September 27 \u2013 October 1, 2022. The presentation will be given during the Cancer: Innovations in Molecular Imaging session. Details of the oral presentation are as follows: Presentation … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48357","6":"format-standard","7":"category-industry"},"yoast_head":"\nOncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced a presentation of data from its ongoing Phase 2 study of pegsitacianine at the World Molecular Imaging Congress (WMIC), occurring September 27 \u2013 October 1, 2022. The presentation will be given during the Cancer: Innovations in Molecular Imaging session. Details of the oral presentation are as follows: Presentation ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T11:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220914005116\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022\",\"datePublished\":\"2022-09-14T11:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/\"},\"wordCount\":291,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005116\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/\",\"name\":\"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005116\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\",\"datePublished\":\"2022-09-14T11:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005116\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005116\\\/en\\\/827960\\\/21\\\/Onconano_Horizontal_Logo_full_color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/","og_locale":"en_US","og_type":"article","og_title":"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022 - Pharma Trend","og_description":"SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced a presentation of data from its ongoing Phase 2 study of pegsitacianine at the World Molecular Imaging Congress (WMIC), occurring September 27 \u2013 October 1, 2022. The presentation will be given during the Cancer: Innovations in Molecular Imaging session. Details of the oral presentation are as follows: Presentation ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-14T11:02:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220914005116\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022","datePublished":"2022-09-14T11:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/"},"wordCount":291,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005116\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/","url":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/","name":"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005116\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","datePublished":"2022-09-14T11:02:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220914005116\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220914005116\/en\/827960\/21\/Onconano_Horizontal_Logo_full_color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/onconano-medicine-announces-oral-presentation-of-phase-2-study-data-at-the-world-molecular-imaging-congress-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48357"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48357\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}